A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity
Latest Information Update: 03 Sep 2024
At a glance
- Drugs ECC-5004 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms VISTA
- Sponsors AstraZeneca
- 03 Sep 2024 New trial record